Prognostic and predictive values of the PIK3CA gene mutation in patients with breast cancer


DOI: https://dx.doi.org/10.18565/pharmateca.2019.7.10-20

T.Yu. Semiglazova (1, 2), I.V. Sorokina (3)

1) N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia; 2) North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia; 3) OOO Novartis Pharma, Moscow Russia
The principles of treatment for HR+ HER2-metastatic breast cancer (mBC) for a long period of time remained unchanged. Consistent use of various endocrinotherapy options provided a significant increase in overall and disease-free survival rates with maintaining a high quality of life. However, over time, patients has a progress of disease due to development of resistance to treatment. Evaluation of the causes and ways to overcome resistance to hormone therapy has led to the discovery of powerful new treatment options for patients with HR+ HER2-mBC. The cross-interaction of various signaling cascades in the cell as a result of acquired mutations of estrogen receptors play fundamental role in the development of resistance to endocrine therapy. The malfunction of the PI3K-mediated cascade is the most frequent disorder in breast cancer and is associated with resistance to endocrine therapy. Phosphatidyl-inositol-3 kinase (PI3K) as a key coordinator of cell growth and vital processes has been attracting the attention of scientists for many years. The current review presents the main provisions characterizing the clinical significance of the PIK3CA gene mutation encoding PI3K kinase: the prognostic and predictive role of the PIK3CA gene mutation (PIK3CA+) in all subtypes of breast cancer; and justifies the allocation of a special group of patients in need of therapy that suppresses the PI3K activity.

About the Autors


Corresponding author: TatyanaYu. Semiglazova, MD, Associate Professor, Head of the Department, Leading researcher at the Scientific Department of Innovative Therapeutic Oncology and Rehabilitation, N.N. Petrov National Medical Research Center of Oncology, Professor at the Department of Oncology, North-Western State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russia; e-mail: tsemiglazova@mail.ru, ORCID: https://orcid.org/0000-0002-4305-6691
Address: 68, Leningradskaya Street, Pesochny settlement, St. Petersburg 197758, Russian Federation


Бионика Медиа